SCHEMBL4510358

SCHEMBL4510358

CCOC(=O)c1cc2c(=O)[nH]c(CC3=CCCC3)nc2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.44
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
PIP4K2A P48426 1/20 0.38
PARP1 P09874 1/20 0.38
ATM Q13315 1/20 0.37
HTT P42858 1/20 0.37
FOS P01100 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491807 0.85 PDE5A (0.56) PDE5AALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL4521870 0.83 KMT2A (0.58) ALDH1A1KDM4EGAAHPGDTSHR
SCHEMBL3494101 0.82 PDE5A (0.55) PDE5AALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL3491252 0.80 PDE5A (0.61) PDE5AALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL4520288 0.80 KMT2A (0.57) ALDH1A1KDM4EGAAHPGDTSHR
SCHEMBL4511837 0.78 PDE5A (0.50) PDE5AALDH1A1KDM4EGAAHPGD
SCHEMBL4530199 0.77 SMN1; SMN2 (0.50) PDE5AALDH1A1KDM4ETSHRSMN1; SMN2
SCHEMBL4522382 0.77 PDE5A (0.57) PDE5AALDH1A1KDM4EGAAHPGD
SCHEMBL21153553 0.77 PDE5A (0.37) PDE5AALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL4515609 0.76 PDE5A (0.76) PDE5AALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 PDE5A 25/4885ALDH1A1 2303/4885KDM4E 2859/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 PDE5A 25/4885ALDH1A1 2303/4885KDM4E 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.